Navigation Links
SHL to Invest 40 Million USD in 2013 to Significantly Expand Production Facilities
Date:2/25/2013

Taoyuan, Taiwan (PRWEB) February 25, 2013

SHL announced plans this week to expand production facilities in Taiwan. A leader in the field of drug delivery devices such as auto injectors and pen injectors, SHL has continued to invest heavily in facilities, advanced machinery and R&D. With the rapid growth of the biologic injectable market, device suppliers are under pressure to broaden the range of services that they can provide. SHL has responded by making significant capital investments such as the 40 Million USD that will be spent this year alone.

CEO Roger Samuelsson commented, “Five years ago I signed a letter of intent with the Taiwan government promising to invest 100 Million USD here. We kept our promise and even completed that investment early. Now we will spend another 40 Million USD for 2013. Our auto injector business is one of the key drivers to this expansion of production capacity. Our customers are bringing more biologics to market and SHL is going to ensure that we meet their needs.”

This year SHL will invest primarily in molding, material handling, assembly and automation capabilities. Production will be ramped up at several facilities in Taiwan, Taoyuan One and various NanKan sites. Increased capacity will allow SHL the flexibility to provide higher quantities of devices each month. In addition to auto injectors, SHL produces pen injectors, infusors and inhaler systems. The company now has well over 2,200 staff globally and will be hiring several hundred new employees in Taiwan this year.

About SHL

SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 2,200 staff globally, with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia.

SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.

Our organization consists of several distinct group companies:

SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies
SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use
SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products
SHL Pharma
Provides final assembly, labeling and packaging services of drug delivery devices to the pharmaceutical and biotechnology industries

For additional information visit http://www.shl-group.com or contact us at info (at) shl-group (dot) com

SHL Media Contact
Steven R. Kaufman
Marketing Director
pr (at) shl-group (dot) com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10458242.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
2. VIC Investor Network to Significantly Accelerate Technology Company Growth
3. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
4. PDL BioPharma to Present at Two Upcoming Investor Conferences
5. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. Amarantus BioScience to Present at the 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
11. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 25, 2017 , ... Franz Inc ., an early ... and market leader for Semantic Graph Database technology, today announced ... most effective system for developing and deploying applications to solve the challenges developers ...
(Date:4/25/2017)... GREENVILLE, SC (PRWEB) , ... April 25, 2017 ... ... SC-based Piedmont Physical Medicine & Rehabilitation, P.A. , proudly announced today that ... will officially commence his duties on May 15, 2017. , Dr. Terzella completed ...
(Date:4/24/2017)... Linda, Ca (PRWEB) , ... April 24, 2017 ... ... protect proteins from thermal denaturation in a cellular milieu; however, the broad application ... a lack of simple platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays ...
(Date:4/21/2017)... TX (PRWEB) , ... April 21, 2017 , ... Having ... than a year, Formaspace is pleased to introduce it to top lab design architects ... Formaspace CEO Jeff Turk and VP of Industrial Design and Engineering Greg Casey will ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):